Journal of Society of Preventive Korean Medicine (대한예방한의학회지)

Society of Preventive Korean Medicine (대한예방한의학회)
권호 표지
DOI QR코드

DOI QR Code

Reference value of serum amyloid P : a systematic review

혈청 아밀로이드 P (SAP)의 정상 참고치 탐색을 위한 문헌 고찰

  • Park, Sunju (Department of Preventive Medicine, College of Korean Medicine, Daejeon University) ;
  • Jung, Jeeyoun (Clinical Medicine Division, Korea Institute of Oriental Medicine) ;
  • Jang, Soobin (Clinical Medicine Division, Korea Institute of Oriental Medicine)
  • 박선주 (대전대학교 한의과대학 예방의학교실) ;
  • 정지연 (한국한의학연구원 임상의학부) ;
  • 장수빈 (한국한의학연구원 임상의학부)
  • Received : 2019.08.01
  • Accepted : 2019.08.19
  • Published : 2019.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The aim of this study was to examine the reference value of biomarker serum amyloid p (SAP) to diagnose blood stasis objectively. Methods : Pubmed-Medline, Cochrane library, EMBASE were searched using the key words 'SAP' and 'serum amyloid p' in June 2018. Original articles of human adults that published in English, studies that recruited from the clinical research settings or well defined population based cohorts were only included. Results : A total of 12 studies were selected to extract the reference value of SAP. It was between 8.5 ng/mL (0.0085 mg/L) to 57.5 mg/L. Although the disease varied, most of them showed elevated SAP levels in the disease group (1.1-1.5 times). Conclusions : This study is meaningful in that it summarizes the results of previous researches of SAP, which has the potential to be diagnostic index of blood stasis.

Keywords

References

  1. Jang S, Kang BG, Ko MM, Jung J. Development of questionnaire for metabolic disease with blood stasis: A Delphi survey. Journal of Society of Preventive Korean Medicine. 2018;22(3):83-89. https://doi.org/10.25153/spkom.2018.22.3.008
  2. Chen KJ. Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy. Chin J Integr Med. 2012;18(12): 891-896. https://doi.org/10.1007/s11655-012-1291-5
  3. Bai D, Song J. Plasma metabolic biomarkers for syndrome of phlegm and blood stasis in hyperlipidemia and atherosclerosis. J Tradit Chin Med. 2012;32(4):578-583. https://doi.org/10.1016/S0254-6272(13)60074-6
  4. 만성질환 현황과 이슈 (만성질환 Fact book), 질병관리본부, 2018
  5. Kang BK, Park TY, Lee JA, Jung J, Lee MS. Development of a blood stasis syndrome questionnaire and its reliability and validity. European Journal of Integrative Medicine, 2016;8(6):942-946. https://doi.org/10.1016/j.eujim.2016.07.003
  6. Terasawa M. Scientific approach to OKESTU (Blood stasis) syndrome. J pn Soc Oriental Med, 1998;48:409-436
  7. Yao KW, Chu FY, Wang J. A clinical epidemiological study of the quantitative diagnosis scale of blood stasis syndrome. Chin J Integr Med. 2011;17(3): 200-204. https://doi.org/10.1007/s11655-011-0667-5
  8. Jung J, Cha MH, Lee H, Ko MM, Lee JA, Lee S, et al. The association of C-reactive protein and serum amyloid P with blood stasis syndrome in Traditional Korean Medicine for general disease conditions: A crosssectional, observational study. European Journal of Integrative Medicine, 2018;8(4):432-437. https://doi.org/10.1016/j.eujim.2016.02.010
  9. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid. 1997;4(4):274-295. https://doi.org/10.3109/13506129709003838
  10. Pilling D, Gomer RH. The development of serum amyloid P as a possible therapeutic. Front Immunol. 2018;9:2328. https://doi.org/10.3389/fimmu.2018.02328
  11. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci. USA. 1995;92(10):4299-4303 https://doi.org/10.1073/pnas.92.10.4299
  12. Li XA, Hatanaka K, Ishibashi-Ueda H, Yutani C, Yamamoto A. Characterization of serum amyloid P component from human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995;15(2):252-257. https://doi.org/10.1161/01.ATV.15.2.252
  13. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004;89(8):3629-3643. https://doi.org/10.1210/jc.2004-0405
  14. Dillingh MR, van den Blink B, Moerland M, van Dongen MGJ, Levi M, Kleinjan A, et al. Recombinant human serumamyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulmonary Pharmacol Therapeut. 2013;26(6):672-676. https://doi.org/10.1016/j.pupt.2013.01.008
  15. Bijl M, Bootsma H, Van Der Geld Y, Limburg PC, Kallenberg CGM, Van Rijswijk MH. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Annals of the rheumatic diseases. 2004;63(7):831-5. https://doi.org/10.1136/ard.2002.004796
  16. Bir E, Lok CAR, Hack CE, van der Post JAM, Schaap MCL, Sturk A, et al. Cell-derived microparticles and complement activation in preeclampsia versus normal pregnancy. Placenta. 2007;28(8-9):928-35. https://doi.org/10.1016/j.placenta.2007.02.008
  17. Hashimoto S, Katou M, Dong Y, Murakami K, Terada S, Inoue M. Effects of hormone replacement therapy on serum amyloid P component in postmenopausal women. Maturitas. 1997;26(2):113-9. https://doi.org/10.1016/S0378-5122(96)01086-9
  18. Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochemical and biophysical research communications. 1994;201 (2):722-6. https://doi.org/10.1006/bbrc.1994.1760
  19. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Serum amyloid P and cardiovascular disease in older men and women: Results from the cardiovascular health study. Arteriosclerosis, thrombosis, and vascular biology. 2007;27(2):352-8. https://doi.org/10.1161/01.ATV.0000254150.97741.fe
  20. Mukamal KJ, Jenny NS, Tracy RP, Siscovick DS. Alcohol consumption, interleukin-6 and apolipoprotein E genotypes, and concentrations of interleukin-6 and serum amyloid P in older adults. American Journal of Clinical Nutrition. 2007;86(2):444-50. https://doi.org/10.1093/ajcn/86.2.444
  21. Mulder SD, Hack CE, Van Der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. Journal of Alzheimer's Disease. 2010 ;22(4):1073-9.
  22. Nelson SR, Tennent GA, Sethi D, Gower PE, Ballardie FW, Amatayakul-Chantler S, et al. Serum amyloid P component in chronic renal failure and dialysis. Clinica Chimica Acta. 1991;200(2-3):191-200. https://doi.org/10.1016/0009-8981(91)90090-Y
  23. Nybo M, Olsen H, Jeune B, Andersen-Ranberg K, Nielsen EH, Svehag SE. Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dementia and geriatric cognitive disorders. 1998;9(3):126-9. https://doi.org/10.1159/000017035
  24. Pepys MB, Becker GJ, Dyck RF, et al. Studies of human serum amyloid P-component (SAP) in relation to coagulation. Clinica Chimica Acta. 1980;105(1):83-91. https://doi.org/10.1016/0009-8981(80)90095-9
  25. Van Eijk IC, Tushuizen ME, Sturk A, Dijkmans BAC, Boers M, Voskuyl AE, et al. Circulating microparticles remain associated with complement activation despite intensive antiinflammatory therapy in early rheumatoid arthritis. Annals of the rheumatic diseases. 2010;69(7):1378-82. https://doi.org/10.1136/ard.2009.118372
  26. Ridker PM. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003;108(12):e81-85. https://doi.org/10.1161/01.CIR.0000093381.57779.67